[10] The first amylin analogue to reach the clinic, pramlintide, demonstrated that the pathway could be drugged, but native-style amylin analogues are short-acting and were used as multiple-daily injections, which limited their appeal for weight management
The research here is still maturing, but it is a clinically meaningful finding for anyone whose obesity has been accompanied by joint deterioration
Retatrutide pros Triple mechanism of action : Retatrutide targets GLP-1, GIP, and GCG, which could offer a more comprehensive approach to weight loss, blood sugar control, and metabolic health, potentially providing superior benefits over dual agonists like tirzepatide
Patients with obesity on GLP-1 medicines improve their body composition without negatively affecting strength
It is being studied mainly for obesity, with additional research into type 2 diabetes and other metabolic conditions
It happens quietly, without you realizing it